IVIG

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myasthenia Gravid

Conditions

Myasthenia Gravid

Trial Timeline

Mar 1, 2007 → Jul 1, 2010

NCT ID

NCT01179893

About IVIG

IVIG is a approved stage product being developed by Grifols for Myasthenia Gravid. The current trial status is completed. This product is registered under clinical trial identifier NCT01179893. Target conditions include Myasthenia Gravid.

What happened to similar drugs?

4 of 20 similar drugs in Myasthenia Gravid were approved

Approved (4) Terminated (2) Active (14)

✅RozanolixizumabUCBApproved

✅IV efgartigimodArgenxApproved

✅EfgartigimodArgenxApproved

✅Efgartigimod PH20 SCArgenxApproved

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02043379	Pre-clinical	Completed	May 1, 2014	Jun 1, 2015	Hypogammaglobulinemia
NCT01841619	Phase 1	Completed	Mar 1, 2013	Nov 1, 2014	Cutaneous Lupus Erythematosus
NCT01179893	Approved	Completed	Mar 1, 2007	Jul 1, 2010	Myasthenia Gravid
NCT00115778	Phase 2	Completed	Jun 1, 2005	Aug 1, 2010	Hypogammaglobulinemia

Competing Products

20 competing products in Myasthenia Gravid

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44